Please assess the completion status of the following clinical trial:

Trial Title: The Potential of Camostat in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Aged ≥18~* Willing to participate and fill out a daily symptom diary~* Willing to take the parameters such as blood oxygenation and temperature~* Willing to attend follow-up visits both by phone as at the clinic~* Capable of understanding the commitment in the trial~* Signed informed consent~* Signs and symptoms suggestive of COVID disease in absence of hospitalization criteria as defined by the flowchart used at the emergency department of our institution (appendix 4), present for maximum 5 days and confirmed by PCR.~* OR documented COVID-19 infection by PCR with CT value below the threshold of 30 in asymptomatic individuals.~* For women of childbearing potential\*: they should be willing to use highly effective method of contraception during treatment and until the end of study defined as having a failure rate of less than 1% per year when used consistently and correctly.~Such methods include:~* combined (estrogen and progestogen containing) hormonal contraception~* associated with inhibition of ovulation: oral, intravaginal or transdermal~* progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable~* intrauterine device (IUD) and intrauterine hormone-releasing system ( IUS)~* bilateral tubal occlusion~* vasectomised partner~* sexual abstinence~  * For men of reproductive potential\*\*: condom should be used as contraception during treatment and until the end of study when having a partner of childbearing potential~    * a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.~      * a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.~Exclusion Criteria~* Inability to make a decision to participate~* Pregnant or breast feeding~* Inability to take oral medication~* Inability to provide informed written consent~* Known hypersensitivity towards Camostat or other Serine protease inhibitors~* Any condition that, in the Investigator's opinion, prevents adequate compliance with study therapy.~* Any COVID infection at risk for hospitalisation as described in the emergency department flowchart (cfr appendix 4)~* With regard to exclusion of women of child-bearing potential, women who tell us they know they are pregnant are excluded. All women of child-bearing potential who test positive for pregnancy by urine test at first visit are excluded.~* Severe chronic pancreatitis requiring suction of gastric juice, fasting or abstention from drinking~* Postoperative reflux oesophagitis due to reflux or gastric juice~* Postoperative reflux oesophagitis (if improvement of symptoms is not observed).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Camostat (Type: EXPERIMENTAL): camostat 100mg 3 tablets 3x/day D1-\>D5 (+ possible extension D6-\>D10)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 3 tablets 3x/day D1-\>D5 (+ possible extension D6-\>D10)

Based on this trial design, predict the completion outcome and termination type (if applicable).